When Matching LC-MS/MS Transitions Do Not Prove THCCOOH Identity

Published by THE OKOROCHA FIRM*

Liquid chromatography-tandem mass spectrometry can provide sensitive and selective cannabinoid measurements. But a signal appearing in the expected mass transitions does not, by itself, prove that every part of that signal came from the intended compound.

A published human-serum study illustrates the problem. During method development, Toennes and colleagues observed a previously unrecognized compound that initially co-eluted with 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, commonly abbreviated THCCOOH. The compound produced the same monitored transitions and similar fragmentation behavior. Chromatographic separation, not the transition list alone, exposed the interference.

The expected ions can appear while identity remains disputed

In multiple-reaction monitoring, an instrument selects a precursor ion and monitors specified product ions. Those transitions can be highly informative when they are supported by retention behavior, ion-ratio criteria, reference materials, and a validated method. For the identification framework, see LC-MS/MS ion ratios and retention time in forensic toxicology.

They are not a separate chromatographic dimension. If two compounds have the same nominal precursor mass and generate the same monitored fragments, a short method may collect both signals in the same region. A matching transition therefore answers only part of the identity question.

For general background on acquisition and validation, see LC-MS/MS in Toxicology.

What appeared in authentic serum

The Toennes study concerned an LC-MS/MS method for THC, 11-hydroxy-THC, and THCCOOH in human serum. During development, the investigators observed a shoulder on the THCCOOH peak in authentic samples from cannabis users. They did not observe it in the described blank or fortified samples or in samples from cannabis-abstinent individuals.

That difference matters. A calibrator made by adding THCCOOH to drug-free serum can demonstrate response to the target analyte. It cannot necessarily reproduce every metabolite, isomer, transformation product, or endogenous component that appears after real exposure and biological processing.

The study therefore supports a narrow but important principle: selectivity testing that relies only on fortified materials may miss an interference present in authentic specimens.

Why the compound remained unidentified

After chromatographic separation, the researchers used product-ion and precursor-ion experiments to examine the additional compound. They reported the same molecular mass as THCCOOH and similar fragmentation behavior. Based on those findings, they suggested an isomeric structure and offered a hypothesis concerning the position of a double bond.

The paper did not establish the exact structure. A defensible summary must preserve that boundary. The compound can be described as an unidentified interference that the authors considered apparently isomeric to THCCOOH. It should not be assigned a definitive chemical identity merely because a proposed structure seems plausible.

For background on retention and co-elution, see Chromatography in Toxicology.

A qualifier transition is not a second separation

The interfering compound produced both monitored THCCOOH transitions in the study. Its relative fragment intensities differed, but the mass-spectrometric experiments did not provide selective transitions that cleanly separated the two substances.

Ion ratios can help evaluate whether a response resembles the reference response under the validated method. They do not guarantee uniqueness when another compound produces the same monitored ions. Retention time also must be interpreted in the context of the method's chromatographic resolution. Two compounds can be analytically distinct while appearing insufficiently separated in a fast gradient.

This is why identity criteria work as a system. Transition selection, ion ratios, retention behavior, peak shape, reference materials, authentic specimens, and chromatographic resolution should be evaluated together.

Extending the gradient exposed the interference

The investigators modified the mobile phase and prolonged the gradient to separate the additional compound from THCCOOH. That separation allowed further mass-spectrometric characterization and showed that the apparent THCCOOH region contained responses from analytically distinct compounds.

The paper reported 98 forensic serum samples analyzed with the extended method and 93 evaluated after the exclusions described by the authors. In that study-specific estimate, the additional compound's measured response relative to THCCOOH ranged from 4.5 to 51.0 percent, with a median of 14.6 percent.

Those numbers are not universal correction percentages. They arose from the study's serum samples, extraction, chromatographic conditions, transitions, integration, and estimation procedure. Another method may separate the compounds, respond differently, or not exhibit the same problem.

For the biological distinction among THC and its metabolites, see Cannabis Metabolites.

A chromatographic change requires revalidation

Changing a gradient can improve selectivity, but it can also change retention, peak shape, response, matrix effects, carryover, and run performance. A modified method should therefore be evaluated as a controlled analytical change rather than treated as an informal adjustment.

Toennes and colleagues developed a shorter optimized routine gradient with an initial isocratic phase and then validated the resulting method. They reported acceptable performance under the tested serum-method conditions and compared results obtained with the optimized and extended approaches.

The practical point is not that every laboratory must adopt that exact gradient. It is that a laboratory confronted with a newly recognized interference should demonstrate that its method resolves the problem and continues to satisfy its validation criteria.

For the broader validation framework, see Quality and Validation.

Records needed to examine a disputed THCCOOH result

A meaningful review should request enough information to determine what the method actually distinguished:

• the complete method and validation package in effect on the analysis date;
• specimen matrix and preparation procedure;
• column, mobile phases, gradient, flow, temperature, and injection conditions;
• precursor and product ions, collision settings, dwell times, and acquisition windows;
• identification rules for retention time, ion ratios, and peak shape;
• target-analyte and internal-standard chromatograms for calibrators, controls, and the questioned specimen;
• selectivity studies using blank, fortified, and authentic specimens;
• interference studies and any later method investigations;
• integration settings and records of manual review or reintegration;
• calibration, quality-control, carryover, matrix-effect, recovery, and proficiency-testing records;
• method revisions, change controls, and revalidation data; and
• raw data sufficient to evaluate whether an unresolved shoulder or co-eluting response was present.

A reported concentration may be numerically precise while the identity and integration of the contributing signal remain disputed. The records should show how the laboratory distinguished the target compound from plausible interferences under its own method.

The defensible conclusion preserves the method limits

The Toennes study does not show that all THCCOOH results are wrong or that every LC-MS/MS cannabinoid method has the same interference. It shows that authentic specimens can expose a selectivity problem that fortified materials do not reveal, and that matching monitored transitions may not resolve an isomeric interference without adequate chromatography.

The conclusion in a particular case should follow the laboratory's actual separation, identity criteria, validation, raw data, and specimen matrix. The method must prove what it distinguishes. The name printed beside a peak should not substitute for that proof.

Source

Toennes SW, Hanisch S, Pogoda W, Wunder C, Paulke A. Pitfall in cannabinoid analysis: detection of a previously unrecognized interfering compound in human serum. Analytical and Bioanalytical Chemistry. 2015;407(2):463-470. DOI.

* Read the full Content Disclaimer.